Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Immunomodulatory and Protective Effects of Adipose Tissue-Derived Mesenchymal Stem Cells in an Allograft Islet Composite Transplantation for Experimental Autoimmune Type 1 Diabetes Publisher Pubmed



Mohammadi Ayenehdeh J1, 2 ; Niknam B1, 3 ; Rasouli S4 ; Hashemi SM4 ; Rahavi H1 ; Rezaei N2, 5 ; Soleimani M6 ; Liaeiha A1 ; Niknam MH2 ; Tajik N1
Authors

Source: Immunology Letters Published:2017


Abstract

Background Allogeneic islet transplantation could be an ideal alternative therapy for Type 1 Diabetes Mellitus (T1DM). Adipose Tissue-derived Mesenchymal Stem Cells (AT-MSCs) characterized by immunomodulatory and protective effects may have the potential to improve the outcome of this highly immunogenic transplant. Methods Syngenic AT-MSCs along with allograft islets embedded in hydrogelic composite and transplanted intraperitoneally in Streptozotocin (STZ) induced diabetic C57BL/6 mice. Results In vitro experiments of co-imbedded islets and AT-MSCs in a hydrogel revealed AT-MSCs are able to significantly increase insulin secretion. During a 32 days of post-transplant period, blood glucose monitoring showed a decrease from over 400 mg/dl to less than 150 mg/dl and at the end of 32 days, mice have been dissected and assessed. Graft histopathology demonstrated that hydrogel makes an artificial immune isolation site and AT-MSCs contribute greatly to the reduction of the immune cells infiltration. Analyses of mononuclear cells isolated from Mesenteric Lymph Nodes (MLNs) and spleen showed that AT-MSCs co-transplanted with allograft decreased pro-inflammatory cytokines and increased regulatory cytokines (for both MLNs and spleen) and regulatory T cells (Treg) population (only for MLNs). In addition, real time-PCR assays revealed that transcript levels of IDO, iNOS, and PDX1, significantly increased in allograft islets in the presence of AT-MSCs. Conclusions according to results, this investigation indicates that AT-MSCs can be regarded as promising complementary candidates for engineered-cell therapy using hydrogel composites in islet transplantation. © 2017 European Federation of Immunological Societies
Other Related Docs
11. Differentiation of Wharton's Jelly Derived Mesenchymal Stem Cells Into Insulin Producing Cells, International Journal of Hematology-Oncology and Stem Cell Research (2018)
18. Immunoengineering Biomaterials in Cell-Based Therapy for Type 1 Diabetes, Tissue Engineering - Part B: Reviews (2022)